Thompson Siegel & Walmsley LLC
- SEC CIK
- 0001008322
- Latest filing
- Aug 11, 2026
XERS holding history
Xeris Biopharma Holdings, Inc. in every 13F filed by Thompson Siegel & Walmsley LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
XERS overviewAll 13F holders of XERSFull Q2 2026 holdings
- Shares (Q2 2026)
- 64,320
- Value
- $509.0K
- % of portfolio
- <0.1%
- Quarters held
- 12
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 64,320 | $509.0K | <0.1% | −22,000−25.5% | Reduced | Holders |
| Q1 2026 | 86,320 | $501.0K | <0.1% | −14,564−14.4% | Reduced | Holders |
| Q4 2025 | 100,884 | $792.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2025 | 100,884 | $821.0K | <0.1% | −165,503−62.1% | Reduced | Holders |
| Q2 2025 | 266,387 | $1.24M | <0.1% | +93,603+54.2% | Added | Holders |
| Q1 2025 | 172,784 | $949.0K | <0.1% | +20,000+13.1% | Added | Holders |
| Q4 2024 | 152,784 | $518.0K | <0.1% | −20,000−11.6% | Reduced | Holders |
| Q3 2024 | 172,784 | $492.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2024 | 172,784 | $389.0K | <0.1% | −17,216−9.1% | Reduced | Holders |
| Q1 2024 | 190,000 | $420.0K | <0.1% | +190,000 | New | Holders |
| Q3 2021 | 0 | $0 | 0.0% | −62,000−100.0% | Sold out | Holders |
| Q2 2021 | 62,000 | $252.0K | <0.1% | +17,000+37.8% | Added | Holders |
| Q1 2021 | 45,000 | $203.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.